describes the normal interactions between neurotrophic factors, the HPA-axis and circadian rhythm, as indicated by levels of BDNF, cortisol and melatonin, and the alterations in these intricately balanced networks in HD. We also discuss the implications of these alterations on the neurobiology of HD and the potential to result in hypothalamic, circadian, and sleep pathologies. Measurable alterations in these pathways provide targets that, if treated early, may reduce degeneration of brain structures. We therefore focus here on the means by which multidisciplinary therapy could be utilised as a non-pharmaceutical approach to restore the balance of these pathways.
Introduction
Huntington's disease (HD) is a fatal autosomal dominant neurodegenerative disease caused by an expanded cytosine-adenine-guanine (CAG) repeat sequence in exon 1 of the Huntingtin gene (HTT) (1) . This expanded sequence encodes a mutant version of the protein, huntingtin (mHTT), which is associated with ubiquitous molecular and cellular anomalies, widespread neuronal dysfunction and cell loss (2) and the presentation of motor and non-motor features, including progressive impairments in motor control, cognitive function and mood (3) .
Evidence also indicates that individuals suffer from sleep disturbances (4-9), autonomic abnormalities (e.g. hyperhidrosis, micturition disturbances, swallowing difficulties, sexual dysfunction, altered heart rate variability) (10, 11) and metabolic irregularities (12, 13) , with some non-motor features, such as cognitive and sleep abnormalities, emerging years before the onset of motor signs (14, 15) .
Although the pathophysiology underlying the development and progression of these clinical features is complex, the accompanying alterations in neuroendocrine signalling, including cortisol (16, 17) and melatonin (18, 19) release, and changes in circadian rhythmicity (20, 21) suggest that the activity of the hypothalamic-pituitary-adrenal (HPA) axis and the suprachiasmatic nucleus (SCN) are impaired in HD (see Table 1 for summary of HD pathologies relevant to this review). Neuropathological changes including volume loss, the loss of orexin-releasing neurons and decreased protein levels of vasoactive intestinal peptide (VIP) and arginine vasopressin (AVP) in the hypothalamus support this supposition (22) (23) (24) .
The HPA-axis is central to neuroendocrine signalling. Indeed, an intricate balance exists between neuroendocrine signalling and expression of neurotrophic factors, particularly brainderived neurotrophic factor (BDNF) (25, 26) . In this review, we present for the first time the biological impact of HPA-axis dysfunction on circadian rhythm, neuroendocrine signalling, and neurotrophic factor support in HD (for a diagrammatic view, see Figure 1 ). We also draw on existing evidence in animal models and patients with HD and other disorders to review nonpharmaceutical treatment strategies, particularly multidisciplinary therapy, exercise, cognitive therapy and social interaction, which may positively impact on HPA-axis dysfunction and potential downstream mechanisms and thereby delay disease onset in individuals with premanifest HD. Since candidate pharmaceutical treatment strategies for HD have been reviewed recently (27) , here we detail non-pharmaceutical multidisciplinary approaches as they have been reported to exert beneficial effects on HPA-axis function, circadian rhythm and BDNF, are of minimal cost and can be implemented throughout life with few side effects.
Normal function of the HPA-axis and the SCN
The structures of the HPA-axis, including the hypothalamus, pituitary and adrenal glands, function in a tightly regulated manner to control responses to physiological and psychological stress, autonomic and immune functions and sleep-wake behaviour through the release of hormones, such as cortisol, in a circadian manner (28) (29) (30) .
The paraventricular nucleus (PVN) releases corticotrophin releasing factor (CRF) into the hypophyseal portal system, where it stimulates the release of adrenocorticotrophic hormone (ACTH) from the corticotropes of the anterior pituitary (31) . ACTH is released into the systemic circulation and stimulates the adrenal cortex to release glucocorticoids, such as corticosterone in mice and cortisol in humans, which regulate responses to stress in central and peripheral systems. These glucocorticoids then provide negative feedback, inhibiting further release of CRF and ACTH by binding to glucocorticoid receptors (GRs) at the PVN and pituitary level, inhibiting further HPA-axis activation via glucocorticoid response elements (GREs) (32) .
Glucocorticoid release is subject to inputs from other brain regions, particularly the amygdala, stria terminalis and hippocampus, which are all regions fundamentally involved in emotional regulation and memory (33) . However the basal circadian release of glucocorticoids is facilitated by the connection between the PVN and SCN.
The SCN is located in the anterior hypothalamus and functions as the central circadian clock that is the principle site of circadian rhythm coordination in mammals (34). The SCN receives information from the retina and other brain regions and synchronises the circadian rhythms of the organism emerging at cellular, physiological and behavioural levels to various zeitgebers, the most important of which is ambient light. Synchronization is mediated through neural and humoral signals. On a molecular level the circadian rhythm in mammals is based on an autoregulatory transcriptional-translational feedback mechanism involving CLOCK and BMAL1 transcription factors and PERIOD (PER1, 2 and 3) and CRYPTOCHROME (CRY 1 and 2) core clock genes (35) . This molecular clock regulates a considerable proportion of the human genome. Importantly, through its connections with the PVN and mediation of the HPAaxis, the SCN controls daily variations in melatonin and cortisol release which are involved, amongst other things, in sleep-wake behaviour and autonomic arousal regulation.
More specifically, activity of the SCN is synchronised to the environmental light-dark cycle directly through the retinal-hypothalamic tract and indirectly through the retinogeniculate pathways and conveys this information to other hypothalamic nuclei, the reticular formation and the pineal gland, coordinating the diurnal activities of these brain regions (36) . Melatonin coordinates circadian rhythms in response to the day-night cycle and initiates the thermoregulatory cascade, decreasing core body temperature to induce sleepiness (36, 37) . The circadian variation of core body temperature is also associated with the internal structure of sleep, particularly with the circadian rhythm of REM (38) .
Stress and the role of cortisol
Cortisol secretion follows a circadian rhythm in individuals with normal sleep-wake cycles.
Within the first 30 minutes of awakening, cortisol levels increase by up to 75% (39) . Cortisol levels then tend to plateau and around midnight reach their nadir. There is large variation in circadian cortisol levels between individuals, however morning cortisol levels are relatively stable intra-individually, allowing for measurement of the cortisol awakening response (CAR), which serves as an indication of HPA-axis function and circadian rhythmicity (40) .
In addition to its natural circadian rhythm, cortisol is released in response to physiological and psychological stress (41). Stress has many contributing factors and occurs when environmental 
Pathological effects of chronic glucocorticoid release
Significant increases in the CAR and daily cortisol output have been documented in premanifest HD (preHD) compared to healthy controls and manifest HD (17, 50, 51) , which implies disruption of the circadian rhythm and therefore of the HPA-axis (16, 22) . 
Effects of glucocorticoids on BDNF
BDNF is essential for survival, differentiation and outgrowth of neurons in the central and peripheral nervous systems and protects neurons from excitotoxin-induced degeneration (62, 63). BDNF is synthesised in cortical neurons and delivered to the striatum via axonal transport of vesicles (64, 65) . BDNF deficits have been documented in cell lines expressing mHTT and in brains of HD mouse models and patients at post-mortem (66) (67) (68) (69) . Analyses of post-mortem brain tissue of four HD subjects indicated regional BDNF deficits of between 53% and 82% in the caudate and putamen compared to age-matched controls (66, 67) , suggesting that volume loss in these regions may, at least in part, be mediated by a lack of neurotrophic factor support.
Significantly elevated glucocorticoids have been reported to decrease the expression of BDNF in animal models and other clinical populations (25, 26) . Chronic stress in rodents induced by repeated restraint results in a negative correlation between plasma glucocorticoid levels and hippocampal BDNF mRNA expression (70, 71) . Furthermore, exogenous administration of glucocorticoids is associated with a transient, dose-dependent reduction in BDNF mRNA and protein in the hippocampus of adrenalectomized (ADX) rodent models (72, 73) . However, five days of oral corticosterone treatment in the R6/1 HD mouse model did not significantly affect hippocampal BDNF expression, emphasising the need to characterise the effects of chronic elevated stress on BDNF levels in HD animal models and patients. It is conceivable that elevated glucocorticoid levels, as observed in preHD, contribute to decreased BDNF expression, thereby potentiating neuronal dysfunction and cell loss in cortical and sub-cortical brain structures.
In addition to supporting normal neuronal functioning, BDNF is thought to be integral in the homeostatic regulation of sleep (74) . Alterations in BDNF signalling as a result of irregular cortisol regulation may potentiate sleep deficits, which are evident early in HD. The interplay between glucocorticoids, neurotrophic factor support and sleep are not well understood but are likely to be important considerations in better understanding the interaction of the HPA-axis and circadian rhythm disruption as features of HD.
Pathologies of the HPA-axis and SCN in HD
mHTT causes progressive neuronal dysfunction and cell loss in striatal and extra-striatal regions, including the hypothalamic nuclei (14, 75) . Studies in mouse models report significant degeneration of the hypothalamus, as well as pituitary and adrenal pathologies (76) (77) (78) (79) . Post-mortem and structural imaging studies in HD mutation carriers have reported volume loss in the hypothalamus, with significant hypothalamic nuclear atrophy, neuronal loss (particularly that of the nucleus tuberalis lateralis (NTL) and lateral hypothalamus (80, 81) ) and microglial activation (22, (82) (83) (84) . Post-mortem studies have also reported loss of orexin-releasing neurons, responsible for innervating the SCN, in the hypothalamus in HD (24, 85) . Loss of this neuronal population is thought to contribute to circadian rhythm disturbances, HPA-axis dysfunction and subsequent alterations in cortisol release (24) . Moreover, HPA-axis dysregulation has been proposed as a contributing factor to co-morbid depression in neurodegenerative diseases, including HD (for a comprehensive review, see 86).
Hypothalamic atrophy has also been reported in preHD individuals using voxel-based morphometry (VBM) (23) . This may, at least in part, explain the observed alterations in cortisol release in preHD. A recent study, however, reported no hypothalamic volume loss in preHD individuals at a 12 month follow-up scan (87) . These conflicting findings reinforce the need to better characterise hypothalamic and other regional volumetric changes in preHD, and determine whether such changes mediate or contribute to circadian rhythm disturbances and clinical features in HD.
Circadian rhythm disruption in HD
Circadian rhythmicity is progressively disrupted in HD, suggesting a possible bi-directional relationship with the neurodegenerative disease process (for a review see 88) . Support for this notion comes from transgenic animal models of HD, such as in the R6/2, R6/1 and BACHD mice, which have shown that circadian disruption precedes the presentation of disease features (20, 89, 90) . Furthermore, humans with manifest HD also display circadian rhythm abnormalities, with disturbances in rest-activity profiles and abnormal day-night ratios, as well as alterations in sleep-wake timing and melatonin and cortisol profiles (20, 88, 91) . The neurobiology underlying these changes has yet to be clarified.
Several studies point to alterations in the SCN as being central to circadian disruptions in HD.
For example, in the R6/2 mouse model of HD the rhythmic transcription of core clock genes in the SCN and other brain regions is disrupted in vivo, but then rescued when assessed in in vitro explants, suggesting that circadian deficits are due to alterations of the intrinsic circuitry of the SCN (20, 90) . This is supported by a reduced circadian rhythm in spontaneous electrical activity in SCN neurons in BACHD transgenic mice (89) . Histopathological studies reveal 
Melatonin and sleep disturbance in HD
Melatonin promotes the onset of sleep by inducing the thermoregulatory cascade (37).
Significant decreases in mean and acrophase (times of peak rhythm) melatonin levels have been reported in manifest HD, with trends towards decreased melatonin levels in preHD (18) .
A temporal shift in melatonin release has also been documented in HD mutation carriers, which could explain documented sleep disturbances (18) . The morning rise phase of melatonin has also been shown to be delayed in HD individuals (19) , which provides a mechanism underlying the delayed sleep-wake timing reported to occur in these patients (21, 104 ). The precise mechanism responsible for the decrease or delayed melatonin levels observed in HD is unclear, but could potentially be attributed to the progressive neuronal dysfunction in the SCN (18, 92) .
Disrupted or restricted sleep leads to increased activity of the HPA-axis (105) . Acute sleep deprivation is associated with increased sympathetic activation, reflected by increases in heart rate and blood pressure (100) and has been described as a chronic stressor that can elevate glucocorticoids and exacerbate disease pathways, such as neuronal dysfunction and degeneration (106, 107) . It is also important to note that disturbances in sleep, particularly disruption of slow wave sleep and decreased sleep duration, result in declines in cognitive and motor performance, as well as altered mood (108) (109) (110) (111) . Furthermore, a recent study by showed that sleep disruption is evident in preHD, characterised by a fragmented sleep profile and a decrease in theta power during REM sleep (9) . These features were associated with disease burden score. It is notable that sleep deficits seem to appear at a time when cognitive impairments also start to emerge, indicating a potential relationship between these disease features.
Sleep deficits are of particular interest in HD, as cognitive functions associated with both the hippocampus and PFC are affected in this population before disease onset (14) , and can be negatively impacted by sleep disturbances, as well as increased glucocorticoids (120) (121) (122) .
Ultimately, alterations in circadian rhythm marked by changes in the molecular clock and facilitated by hypothalamic and SCN pathologies, could result in changes in melatonin release and increased cortisol levels, with resultant sleep disturbances, which are likely to potentiate neurodegeneration and associated changes in cognitive and motor deficits and mood disturbances in HD.
Environmental enrichment: A comprehensive non-pharmaceutical strategy to reduce the impact of circadian rhythm disturbances and HPA-axis dysfunction in HD
Several non-pharmaceutical strategies have been employed to ameliorate circadian and HPAaxis dysfunctions in mouse models of HD, including bright light and behavioural therapy (123) and environmental enrichment (EE). EE is an experimental approach reported to change intrinsic and behavioural rest-activity circadian rhythmicity and glucocorticoid release and has been widely studied in transgenic and drug-induced AD, Parkinson's disease (PD) and HD mouse models (reviewed in 124). EE employs exercise, cognitive and sensory stimulation to promote neurogenesis and improve cognitive and behavioural function, motor features and overall pathological processes underpinning these clinical features (124) (125) (126) .
The first demonstration that EE could be beneficial in a genetic animal model involved HD mice (127) and demonstrated that EE could delay disease onset and progression displayed by improved motor function and preserved peristriatal brain structures. Ensuing investigations revealed that EE has cognitive and body composition benefits in R6/2 (128) and N171 HD mice (129), while also ameliorating cognitive deficits (130) and affective (depressive-like) abnormalities in R6/1 mice (131, 132) . Considering the more rapid disease progression of the R6/2 model compared to R6/1, this demonstrates that EE is effective in both rapid and more prolonged disease progression phenotypes.
EE has been reported to increase the length of neuronal dendrites in the dorsomedial nucleus of the hypothalamus, which is thought to play a role in the circadian control of sleep and waking behaviours (133) , and alter stress reactivity in outbred rats (134, 135) , and in the female R6/1 mouse model, EE modulates HPA-axis activity (76) . Furthermore, circadian rhythm disturbances have also been ameliorated through bright light therapy and exercise in the R6/2 mouse model (123) . This demonstrates that environmental interventions have the potential to modulate functions of the HPA-axis and the SCN in mouse models of HD and warrants further investigation into whether this can be recapitulated in the human HD population.
Moreover, EE in HD mice has been shown to rescue BDNF protein levels in the striatum and hippocampus (136) , with associated delays in disease onset, including a reduction in cognitive decline (130) . These studies suggest that modulation of HPA-axis function and circadian rhythm facilitated by EE may, at least in part, rescue BDNF levels, ultimately contributing to neuroprotection and neurogenesis (137) .
Evidence suggests that physical activity in itself can be beneficial in delaying the progression of HD in mouse models. Pang et al (2006) demonstrated that voluntary wheel running delayed onset of rear paw clasping, a feature of HD in mouse models, ameliorated cognitive deficits and also normalised rearing behaviour (138) . Additionally, wheel running from a juvenile age 
Effects of multidisciplinary therapy on brain volume and potential biomarkers of HD in humans
Preclinical studies show that EE has positive effects on the pathological and clinical course of HD. However translation of EE from the laboratory to the clinic has proven difficult due to the strict parameters of the experimental model, such as diet and housing conditions. Several research teams have, nevertheless, begun to address some of these translational gaps using multidisciplinary therapy; a complex, interdisciplinary therapeutic approach comprising physical activity, cognitive stimulation and social interaction.
Studies evaluating the utility of multidisciplinary therapy have documented significant changes in grey matter volume, as well as improvements in memory, processing speed, balance and gait, mood and quality of life in patients with manifest HD (144) (145) (146) (147) . Recent data from our research programme has shown, in particular, that multidisciplinary therapy increases grey matter volume in the caudate tail and dorsolateral PFC in patients with manifest HD (147) . This therapy has also been reported to improve cognitive function, quality of life and depressive symptoms in patients with mild AD and cognitive impairment without dementia (148) and in PD, multidisciplinary therapy has been reported to improve motor performance, dyskinesias, balance and gait and slow disease progression (149) (150) (151) . The molecular mechanisms driving these neural and clinical changes are yet to be investigated. Several lines of evidence suggest, however, that multidisciplinary therapy may restore normal HPA-axis function, circadian rhythmicity and basal BDNF levels, promoting neural and clinical benefits in HD.
EE is capable of restoring normal HPA-axis function, circadian rhythmicity and basal BDNF levels in HD mouse models (76, 123, 141) , with significant delays in peristriatal degeneration and cognitive and motor decline (130, 138, 139) , which could be facilitated by restoration of the HPA-axis and circadian rhythmicity and increases in BDNF levels. While these positive molecular changes are yet to be reported in patients with HD, evidence from other diseases suggests that multidisciplinary therapy may impact on the neuropathological and clinical course of the disease in a similar fashion to EE. For example, in PD multidisciplinary therapy has been reported to increase serum BDNF levels and lessen clinical burden in the early stages of the disease (152, 153) .
The effects of multidisciplinary therapy on HPA-axis function, stress reactivity and circadian rhythmicity are yet to be investigated in any disease population. Furthermore, the effects of this therapy on BDNF in HD are also yet to be reported. However, the benefits of EE on the HPA-axis, BDNF levels and circadian rhythmicity in HD mouse models, both before disease Higher physical activity levels are associated with increased hippocampal and PFC volume, accompanying improvements in memory in healthy older adults (154, 155) and increased BDNF levels (156, 157) . The latter could be mediated by the continual induction and eventual down-regulation of the stress response due to acute, transient increases in cortisol following exercise (158) , leading to an adaptive stress response. The regulation of circadian rhythmicity and melatonin levels by exercise, indicated by shifts in onset and increases in peak melatonin release (159, 160) , could also facilitate an increase in BDNF and regulation of the HPA-axis, and lead to improvements in brain volume and associated functions.
Cognitive training has also been documented to increase grey matter volume in the cortex in regions involved in episodic memory in individuals with subjective memory impairment, a common risk factor for AD (161) . Furthermore, cognitive training has been shown to reduce stress-related symptoms and improve sleep onset latency and efficiency in individuals with stress-related exhaustion (162) and in older adults with insomnia (163) 
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